Champions Oncology Crecimiento futuro
Future controles de criterios 1/6
Se prevé que los ingresos de Champions Oncology aumenten en un 10.8% al año.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 17.4% |
| Tasa de crecimiento de los ingresos | 11.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 Mar 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28
Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 4/30/2027 | 67 | N/A | 0 | N/A | 1 |
| 4/30/2026 | 59 | N/A | -3 | N/A | 1 |
| 4/30/2025 | 54 | N/A | -7 | N/A | 1 |
| 4/30/2024 | 49 | N/A | -8 | N/A | 1 |
| 1/31/2024 | 49 | -10 | -7 | -5 | N/A |
| 10/31/2023 | 50 | -10 | -5 | -3 | N/A |
| 7/31/2023 | 53 | -8 | -3 | 0 | N/A |
| 4/30/2023 | 54 | -5 | 1 | 4 | N/A |
| 1/31/2023 | 54 | -3 | 3 | 5 | N/A |
| 10/31/2022 | 54 | 0 | 6 | 8 | N/A |
| 7/31/2022 | 52 | 0 | 4 | 6 | N/A |
| 4/30/2022 | 49 | 1 | 4 | 6 | N/A |
| 1/31/2022 | 47 | 0 | 1 | 4 | N/A |
| 10/31/2021 | 44 | 0 | -4 | 0 | N/A |
| 7/31/2021 | 43 | 0 | -4 | -1 | N/A |
| 4/30/2021 | 41 | 0 | -5 | -2 | N/A |
| 1/31/2021 | 39 | -1 | -1 | 3 | N/A |
| 10/31/2020 | 37 | -2 | 0 | 3 | N/A |
| 7/31/2020 | 35 | -1 | 0 | 2 | N/A |
| 4/30/2020 | 32 | -2 | 1 | 3 | N/A |
| 1/31/2020 | 31 | 0 | 0 | 1 | N/A |
| 10/31/2019 | 29 | -1 | 1 | 2 | N/A |
| 7/31/2019 | 28 | -1 | 0 | 1 | N/A |
| 4/30/2019 | 27 | 0 | 1 | 2 | N/A |
| 1/31/2019 | 24 | 0 | 1 | 2 | N/A |
| 10/31/2018 | 23 | 0 | 0 | 1 | N/A |
| 7/31/2018 | 21 | 0 | 1 | 1 | N/A |
| 4/30/2018 | 20 | -1 | -2 | -1 | N/A |
| 1/31/2018 | 19 | -3 | -2 | -1 | N/A |
| 10/31/2017 | 18 | -5 | N/A | -2 | N/A |
| 7/31/2017 | 17 | -5 | N/A | -2 | N/A |
| 4/30/2017 | 15 | -7 | N/A | -3 | N/A |
| 1/31/2017 | 15 | -7 | N/A | -4 | N/A |
| 10/31/2016 | 14 | -8 | N/A | -4 | N/A |
| 7/31/2016 | 12 | -10 | N/A | -6 | N/A |
| 4/30/2016 | 11 | -10 | N/A | -6 | N/A |
| 1/31/2016 | 12 | -12 | N/A | -8 | N/A |
| 10/31/2015 | 11 | -12 | N/A | -10 | N/A |
| 7/31/2015 | 10 | -13 | N/A | -9 | N/A |
| 4/30/2015 | 9 | -13 | N/A | -10 | N/A |
| 1/31/2015 | 8 | -12 | N/A | -7 | N/A |
| 10/31/2014 | 10 | -10 | N/A | -7 | N/A |
| 7/31/2014 | 10 | -9 | N/A | -4 | N/A |
| 4/30/2014 | 12 | -7 | N/A | -3 | N/A |
| 1/31/2014 | 11 | -7 | N/A | -5 | N/A |
| 10/31/2013 | 10 | -8 | N/A | -4 | N/A |
| 7/31/2013 | 9 | -7 | N/A | -5 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de CSBR es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de CSBR crezcan más rápidamente que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de CSBR crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (10.8% al año) de CSBR crezcan más rápidamente que los del mercado US (8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 10.8% al año) de CSBR crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CSBR se prevé que sea elevada dentro de 3 años.